Stem Cell and Exosome Trials are Hoping to Tackle Parkinson’s
In March this year, a ScienceDaily article reported that Mass General is pioneering a Phase 1 clinical trial advancing stem cell therapies for Parkinson’s disease. The trial involves reprogramming patients’ own stem cells into dopamine-producing neurons to replace those lost to the disease. The hospital reports that three of six participants have been treated, with […]
In March this year, a ScienceDaily article reported that Mass General is pioneering a Phase 1 clinical trial advancing stem cell therapies for Parkinson’s disease. The trial involves reprogramming patients’ own stem cells into dopamine-producing neurons to replace those lost to the disease. The hospital reports that three of six participants have been treated, with safety and feasibility under evaluation for the year.
While the Mass General trial focuses on stem cell transplantation, the article also suggested broader mechanisms—like exosome release—that could transform Parkinson’s care by repairing brain damage and enhancing dopamine production.
Exosomes, small vesicles secreted by stem cells, carry proteins, lipids, and RNA that may act as repair signals for damaged neurons. In Parkinson’s, where dopamine-producing cells in the substantia nigra (a part of the brain) degenerate, stem cells could release exosomes to spur neuroregeneration, curb inflammation, and boost dopamine synthesis. This could stabilize symptoms like tremors, rigidity, and slow movement, potentially offering a more enduring solution than levodopa, which only temporarily raises dopamine levels.
Infinite Health Integrative Medicine Center, led by Trip Goolsby, MD, says they’re bringing this science to patients through exosome-based therapies for Parkinson’s. Unlike the trial’s surgical approach, Infinite Health uses exosomes—often derived from stem cells—in a less invasive format, such as intravenous infusion, to cross the blood-brain barrier and promote repair. “Regenerative medicine is revolutionizing how we approach Parkinson’s,” says Dr. Goolsby. “Exosome therapies harness the body’s own healing potential to not just manage symptoms but potentially reverse their progression, giving patients a real shot at reclaiming their lives.” Combined with bio-individualized health optimization, Infinite Health targets dopamine deficits, inflammation, and oxidative stress—key drivers of neuronal loss.
While the trial tests stem cell implants, Infinite Health says its exosome solutions offer a scalable alternative, broadening access to regenerative care. Both efforts mark a shift from symptom management to slowing Parkinson’s progression through biological repair. The company reports that early trial results and Infinite Health’s therapies suggest that patients could gain improved motor stability and quality of life.
Contact:
Infinite Health Integrative Medicine Center
LeNae Goolsby
info@yourinfinitehealth.com
504-323-0025
